Compare GNK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | GERN |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 967.7M | 808.3M |
| IPO Year | 2005 | N/A |
| Metric | GNK | GERN |
|---|---|---|
| Price | $24.05 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $19.00 | $2.17 |
| AVG Volume (30 Days) | 347.4K | ★ 13.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $342,054,000.00 | N/A |
| Revenue This Year | $21.15 | $26.91 |
| Revenue Next Year | $1.41 | $43.75 |
| P/E Ratio | $114.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.66 | $1.04 |
| 52 Week High | $27.25 | $2.01 |
| Indicator | GNK | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 34.40 |
| Support Level | $22.40 | $1.22 |
| Resistance Level | $24.25 | $1.29 |
| Average True Range (ATR) | 0.86 | 0.06 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 17.64 | 21.15 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.